

Patent  
Attorney's Docket No. 033285-019

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

Rudolf WANK

Application No.: 10/687,913

Filing Date: October 20, 2003

For: USE OF STIMULATED PERIPHERAL-  
BLOOD MONONUCLEAR CELLS FOR  
THE TREATMENT OF CANCEROUS  
DISEASES

Group Art Unit: Unassigned

Examiner: Unassigned

**SECOND INFORMATION DISCLOSURE STATEMENT  
TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application:

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (1806) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$\_\_\_\_\_ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$\_\_\_\_\_ is enclosed for the fee due.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,


BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: January 12, 2004

By:

  
Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620



Patent  
Attorney's Docket No. 033285-019

**UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of )  
Rudolf WANK )  
Application No.: 10/687,913 ) Group Art Unit: Unassigned  
Filing Date: October 20, 2003 ) Examiner: Unassigned  
For: USE OF STIMULATED PERIPHERAL- )  
BLOOD MONONUCLEAR CELLS FOR )  
THE TREATMENT OF CANCEROUS )  
DISEASES )

**SECOND INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date: January 12, 2004

By:   
Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620



Substitute for forms 1449A/PTO &amp; 1449B/PTO

**SECOND INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**ATTORNEY'S DKT NO.  
033285-019APPLICATION NO.  
10/687,913APPLICANT  
Rudolf WANKFILING DATE  
October 20, 2002GROUP  
Unassigned**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation Yes No

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	van Leeuwen et al., "T cell antigen-receptor signal transduction," Curr. Opin. Immunol., (1999), 11:242-248.
	Sheehy et al., "HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes," Science, (1975), 188:1308-1310.
	Wank et al., "High risk of squamous cell carcinoma for women with HLA-DQw3," Nature, (1991), 352:723-725.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.